There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Parkinson's disease (PD) is known as a chronic neurodegenerative disorder with a relentlessly
progressive course of illness. Although in recent decades there have been many advances
in symptomatic therapy, there is still no established therapy that will halt or slow
progression in a clinically meaningful way. So far, disease-modification trials have
focused on indices of progression of cardinal motor features such as bradykinesia,
rigidity and tremor as captured by the Unified Parkinson's Disease Rating Scale, and
the emerging need for effective symptomatic dopaminergic therapy. Progression of global
disability in PD, however, is driven by additional factors beyond progressive nigrostriatal
denervation, leading to increasing severity of cardinal motor features. Progressive
pathology in extranigral sites inevitably leads to poorly L-dopa-responsive motor
symptoms such as postural instability, freezing and falls, or non-motor symptoms.
Furthermore, treatment-induced motor complications also contribute to PD disability.
Progression of PD is multidimensional with superimposed age-related co-morbidities.
Hence there is no consensus on how to best implement more clinically meaningful end-points
for disease progression trials that would reflect these complex interactions impacting
on the evolution of global disability in PD. There is an urgent need for biomarkers
identifying preclinical stages of illness and describing disease progression--thus
faithfully reflecting early and advancing neurodegeneration--that could be used in
short-term clinical trials testing putative disease-modifying agents.
Copyright 2009 Elsevier Ltd. All rights reserved.